Compounds > azacitidine

azacitidine and Graft-Versus-Host Disease

azacitidine has been researched along with Graft-Versus-Host Disease in 44 studies

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (6.82)29.6817
2010's30 (68.18)24.3611
2020's11 (25.00)2.80

Authors

AuthorsStudies
Tang, Y; Yan, H; You, Y; Zhou, Z1
Beauvais, D; Chauvet, P; Coiteux, V; Drumez, E; Duhamel, A; Magro, L; Quesnel, B; Srour, M; Wattebled, KJ; Yakoub-Agha, I1
Han, S; Han, Y; Li, X; Pan, T; Qi, J; Wang, H; Xu, X; Yao, Y; Zhou, M1
Abbott, D; Bosma, G; Gutman, JA; Jordan, C; Minhajuddin, M; Pollyea, DA; Winters, AC1
Ishiguro, C; Kawashiri, A; Kurokawa, T; Maeda, Y; Mochizuki, K; Nakagawa, SI1
Holter-Chakrabarty, J; Keruakous, AR; Khawandanah, MO; Schmidt, SA; Selby, G; Yuen, C1
Cadeddu, RP; Christopeit, M; Drusenheimer, N; Esseling, E; Germing, U; Haas, R; Holtick, U; Jäger, P; Klein, S; Kobbe, G; Kröger, N; Mikesch, JH; Rautenberg, C; Scheid, C; Schroeder, T; Stelljes, M; Trenschel, R1
Ali, N; Andrade, L; Baer, L; Balls, JW; Caimi, P; Cao, S; de Lima, M; Fu, P; Goldstein, SC; Metheny, L; Mori, S; Nelson, M; Patel, RD; Smith, M; Smith, T; Tomlinson, B; Varela, JC1
Bai, L; Liu, SB; Ma, X; Qian, CS; Sun, AN; Wang, J; Wang, TJ; Wu, DP; Xu, MZ; Xue, SL; Zhou, HX1
Bin, Z; Guoliang, H; Hongmei, N; Jiangwei, H; Jianlin, C; Liangding, H; Yao, S; Yuhang, L; Zhuoqing, Q1
Ahmed, I; Bishop, R; Craddock, C; Dignan, FL; Elhaneid, M; Hodgkinson, A; Jackson, A; Malladi, R; McIlroy, G; Moss, P; Nunnick, J; Protheroe, R; Siddique, S1
Choi, J; Cooper, ML; DiPersio, JF; Karpova, D; Ritchey, J; Schroeder, MA; Vij, K1
Bornhäuser, M; Bug, G; Germing, U; Geyh, S; Haas, R; Hopfer, O; Klein, S; Kobbe, G; Kondakci, M; Krüger, W; Nachtkamp, K; Platzbecker, U; Rautenberg, C; Schroeder, T; Steinmann, J1
Champlin, RE; Craddock, C; de Lima, M; Giralt, SA; Hetzer, J; Hubbell, B; Laille, E; Oran, B; Papadopoulos, EB; Scott, BL; Skikne, BS; William, BM1
Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH1
Aziz, M; Bandyopathyay, D; Chung, H; Claiborne, J; Clark, W; Hawks, K; McCarty, J; Roberts, C; Simmons, G; Toor, A; Wiedl, C1
Borel, C; Chevallier, P; Garnier, A; Gaugler, B; Guillaume, T; Huynh, A; Labopin, M; Magro, L; Malard, F; Milpied, N; Mohty, M; Moreau, P; Peterlin, P; Rubio, MT; Tabrizi, R; Vigouroux, S; Yakoub-Agha, I1
Jing, Y; Sun, L; Yang, L; Yuan, L1
Inoue, A; Kawakami, C; Takitani, K; Tamai, H1
Bacigalupo, A; Bregante, S; Colombo, N; Di Grazia, C; Dominietto, A; Galaverna, F; Geroldi, S; Ghiso, A; Grasso, R; Gualandi, F; Lamparelli, T; Luchetti, S; Raiola, AM; Stasia, A; Van Lint, MT; Varaldo, R1
Fu, C; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wang, J; Wang, P; Wu, D; Zheng, H; Zhou, J1
Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P1
Fu, C; Han, Y; Jin, Z; Liu, H; Ma, L; Miao, M; Qiu, H; Tang, X; Wang, J; Wang, P; Wu, D; Yan, S; Zheng, H; Zhou, J1
Bhatt, VR; Ganti, AK; Hausmann, H; Maness, LJ; Yuan, J1
Bär, B; Blijlevens, NNM; Bremmers, MEJ; Cruijsen, M; Dolstra, H; Falkenburg, JHF; Hobo, W; Huls, G; Jansen, J; Kester, M; Schaap, NPM; van der Velden, WJFM; Woestenenk, R1
Bôle-Richard, E; Borg, C; Certoux, JM; Deconinck, E; Deschamps, M; Ferrand, C; Gamonet, C; Idirene, I; Larosa, F; Mosseley, AM; Tiberghien, P1
Baron, F; Beguin, Y; Caers, J; Conteduca, G; Delens, L; Delvenne, P; Drion, P; Dubois, S; Ehx, G; Fransolet, G; Hannon, M; Humblet-Baron, S; Muller, J; Somja, J1
Abboud, C; Cashen, A; Choi, J; DiPersio, J; Eissenberg, LG; Fiala, MA; Fletcher, T; Ghobadi, A; Jacoby, M; Liu, J; Pusic, I; Schroeder, MA; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P1
Liu, H; Sun, Z; Tang, B; Tong, J; Zhang, L; Zhang, X; Zheng, C; Zhou, H; Zhu, X1
Abu-Arja, R; Abusin, G; Cabral, L; Ding, H; Hashem, H; Lazarus, HM; Rangarajan, H1
Costeas, PA; Marioli, D; Patmanidi, AL; Pierides, C; Sgourou, A; Spyridonidis, A; Stamou, P; Taraviras, S; Theofani, E; Vittoraki, A1
Champlin, R; Davisson, J; de Lima, M; De Padua Silva, L; Faderl, S; Garcia-Manero, G; Giralt, S; Issa, JP; Kantarjian, H; Kebriaei, P; Ravandi, F1
Bertz, H; Claus, R; Finke, J; Lübbert, M; Marks, R; Rüter, B; Wäsch, R1
Bruns, I; Czibere, A; Fenk, R; Germing, U; Gräf, T; Haas, R; Kobbe, G; Kröger, N; Lind, J; Platzbecker, U; Schröder, T; Zohren, F1
Ballestar, E; Blanco, B; Caballero-Velazquez, T; Carrancio, S; Ciudad, L; Del Cañizo, C; Flores, T; García, JL; González, FJ; Gutierrez-Cosio, S; Hernández-Campo, P; Herrero-Sánchez, C; Pérez-Simon, JA; San Miguel, JF; Sánchez-Abarca, LI; Santamaría, C1
Choi, J; Deych, E; DiPersio, JF; Holt, M; Piwnica-Worms, DR; Prior, JL; Ritchey, J; Shannon, WD1
Braun, TM; Champlin, R; de Lima, M; de Padua Silva, L; Garcia-Manero, G; Giralt, S; Jones, RB; Komanduri, K; Nguyen, HQ; Thall, PF1
Bolaños-Meade, J; Fuchs, EJ; Gore, SD; Jones, RJ; Luznik, L; McDevitt, MA; Smith, BD1
Ahn, SY; Choi, Y; Jeon, M; Jung, AR; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Lee, SB; Lee, YJ; Lee, YS; Park, YH; Seol, M1
Engel, N; Rank, A1
de Lima, M; Koreth, J; Reddy, P1
Cui, Q; Fu, H; Fu, S; Gu, Y; Hu, Y; Huang, H; Liu, L; Sheng, L; Shi, J; Tan, Y; Wu, K; Yu, X1
Andersson, B; Champlin, R; Couriel, D; de Lima, M; Donato, M; Gajewski, J; Giralt, S; Kantarjian, H; Khouri, I; Ravandi, F; Shahjahan, M; van Besien, K1
Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF1

Reviews

4 review(s) available for azacitidine and Graft-Versus-Host Disease

ArticleYear
Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis.
    Expert review of hematology, 2022, Volume: 15, Issue:5

    Topics: Azacitidine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local

2022
PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
    Bone marrow transplantation, 2021, Volume: 56, Issue:5

    Topics: Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Recurrence; Transplantation, Homologous

2021
Epigenomics in hematopoietic transplantation: novel treatment strategies.
    Epigenomics, 2011, Volume: 3, Issue:5

    Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immune Tolerance; Immunologic Factors; T-Lymphocytes, Regulatory

2011
Emerging therapies in hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:1 Suppl

    Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Proteasome Inhibitors; Pyrazines; Vorinostat

2012

Trials

8 trial(s) available for azacitidine and Graft-Versus-Host Disease

ArticleYear
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial.
    Bone marrow transplantation, 2021, Volume: 56, Issue:12

    Topics: Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Quality of Life; Steroids

2021
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:10

    Topics: Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate

2018
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Bone marrow transplantation, 2019, Volume: 54, Issue:11

    Topics: Adolescent; Adult; Aged; Allografts; Azacitidine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Risk Factors; Survival Rate; Unrelated Donors

2019
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:10

    Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Young Adult

2015
Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Leukemia research, 2016, Volume: 49

    Topics: Adult; Aged; Azacitidine; Drug Administration Schedule; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Maximum Tolerated Dose; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome

2016
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
    Bone marrow transplantation, 2009, Volume: 43, Issue:11

    Topics: Adult; Aged; Azacitidine; Decitabine; Disease Progression; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2009
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
    Cancer, 2010, Dec-01, Volume: 116, Issue:23

    Topics: Adult; Aged; Azacitidine; Disease-Free Survival; DNA Methylation; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Transplantation, Homologous

2010
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
    Cancer, 2003, Mar-01, Volume: 97, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Cyclophosphamide; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Survival Analysis; Transplantation Conditioning

2003

Other Studies

32 other study(ies) available for azacitidine and Graft-Versus-Host Disease

ArticleYear
Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Male; Recurrence; RUNX1 Translocation Partner 1 Protein; Transplantation, Homologous

2022
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Annals of hematology, 2022, Volume: 101, Issue:6

    Topics: Azacitidine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Myeloproliferative Disorders; Neoplasms; Prospective Studies; Recurrence; Retrospective Studies; Transplantation Conditioning

2022
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
    Transplantation and cellular therapy, 2022, Volume: 28, Issue:10

    Topics: Adult; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies; Sulfonamides

2022
Donor-derived diffuse large B-cell lymphoma after haploidentical stem cell transplantation for acute myeloid leukemia.
    Journal of clinical and experimental hematopathology : JCEH, 2022, Volume: 62, Issue:3

    Topics: Antilymphocyte Serum; Azacitidine; Busulfan; Epstein-Barr Virus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; HLA Antigens; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Positron Emission Tomography Computed Tomography; Tacrolimus; Transplantation Conditioning

2022
Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
    Hematology/oncology and stem cell therapy, 2023, Jan-12, Volume: 16, Issue:1

    Topics: Adult; Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Recurrence; Retrospective Studies

2023
Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
    Haematologica, 2023, 11-01, Volume: 108, Issue:11

    Topics: Adult; Azacitidine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Myelodysplastic Syndromes; Recurrence; T-Lymphocytes; Transplantation, Homologous

2023
Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leukemia & lymphoma, 2020, Volume: 61, Issue:12

    Topics: Azacitidine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous

2020
Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous

2021
Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.
    Journal of immunology (Baltimore, Md. : 1950), 2017, 05-01, Volume: 198, Issue:9

    Topics: Animals; Azacitidine; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Transcription Factors; Graft vs Host Disease; Graft vs Leukemia Effect; Growth Inhibitors; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Postoperative Complications; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Up-Regulation

2017
Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Annals of hematology, 2018, Volume: 97, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome

2018
[The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies].
    Zhonghua nei ke za zhi, 2018, Sep-01, Volume: 57, Issue:9

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Clinical Protocols; Decitabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning

2018
Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous

2019
Acute graft-versus-host disease in a nonhematopoietic stem cell transplantation candidate treated with decitabine followed by granulocyte colony-stimulating factor-primed peripheral blood stem cells infusion: a special entity of the disease?
    Transfusion, 2014, Volume: 54, Issue:1

    Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Combined Modality Therapy; Decitabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning

2014
Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:5

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Homologous

2014
DLI after haploidentical BMT with post-transplant CY.
    Bone marrow transplantation, 2015, Volume: 50, Issue:1

    Topics: Adolescent; Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Leukemia; Living Donors; Lymphocyte Transfusion; Middle Aged; Recurrence; Survival Rate; Time Factors

2015
[Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:2

    Topics: Azacitidine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Retrospective Studies; Transplantation, Homologous

2015
[Therapeutic efficacies of decitabine application prior to hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia].
    Zhonghua yi xue za zhi, 2015, Mar-31, Volume: 95, Issue:12

    Topics: Azacitidine; Decitabine; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Homologous

2015
Activity of single-agent decitabine in atypical chronic myeloid leukemia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:6

    Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Transplantation, Homologous

2016
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:6

    Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; CD8-Positive T-Lymphocytes; Decitabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2016
Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.
    Gene therapy, 2016, Volume: 23, Issue:8-9

    Topics: Antigens, CD19; Azacitidine; Bone Marrow Transplantation; Caspase 9; DNA Methylation; Genes, Transgenic, Suicide; Genetic Therapy; Graft vs Host Disease; Humans; Jurkat Cells; Organic Chemicals; Transplantation, Homologous

2016
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
    Journal of hematology & oncology, 2016, 07-04, Volume: 9, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Cell Proliferation; DNA Methylation; Drug Administration Schedule; Forkhead Transcription Factors; Graft vs Host Disease; Lymphocyte Count; Mice; Mice, Inbred BALB C; Scleroderma, Systemic; Spleen; T-Lymphocytes, Regulatory

2016
Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia.
    Pediatric transplantation, 2016, Volume: 20, Issue:8

    Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child; Child, Preschool; Cohort Studies; Cord Blood Stem Cell Transplantation; Decitabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome

2016
Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
    Pediatric transplantation, 2017, Volume: 21, Issue:2

    Topics: Adolescent; Azacitidine; Cytotoxins; DNA Damage; Fanconi Anemia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2017
Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease.
    Cytotherapy, 2017, Volume: 19, Issue:4

    Topics: Azacitidine; Cell Culture Techniques; Cell Engineering; Cells, Cultured; Decitabine; DNA Methylation; Gene Expression Regulation; Graft vs Host Disease; HLA-G Antigens; Humans; Immunotherapy, Adoptive; T-Lymphocytes, Regulatory

2017
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
    Bone marrow transplantation, 2010, Volume: 45, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Drug Administration Schedule; Epigenesis, Genetic; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Stem Cell Transplantation; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous

2010
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
    Bone marrow transplantation, 2010, Volume: 45, Issue:5

    Topics: Adult; Aged; Azacitidine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous

2010
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.
    Blood, 2010, Jan-07, Volume: 115, Issue:1

    Topics: Animals; Azacitidine; Bone Marrow Transplantation; Cell Cycle; Cell Proliferation; Cell Survival; DNA Methylation; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Expression Regulation; Graft vs Host Disease; Humans; Immunity; Immunologic Factors; Lymphocyte Activation; Lymphocyte Count; Male; Mice; Promoter Regions, Genetic; Spleen; Survival Analysis; T-Lymphocytes, Regulatory; Transplantation, Homologous

2010
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.
    Blood, 2010, Jul-08, Volume: 116, Issue:1

    Topics: Adoptive Transfer; Animals; Azacitidine; CD4-Positive T-Lymphocytes; Cells, Cultured; Combined Modality Therapy; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; T-Lymphocytes, Regulatory

2010
5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:5

    Topics: Adult; Aged; Azacitidine; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloproliferative Disorders; Prospective Studies; Remission Induction; Salvage Therapy; Secondary Prevention; Transplantation Conditioning; Transplantation, Homologous

2011
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.
    Bone marrow transplantation, 2012, Volume: 47, Issue:3

    Topics: Adult; Aged; Azacitidine; Decitabine; Disease-Free Survival; DNA Methylation; Feasibility Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Risk; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2012
Decitabine facilitates the generation and immunosuppressive function of regulatory γδT cells derived from human peripheral blood mononuclear cells.
    Leukemia, 2013, Volume: 27, Issue:7

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Regulatory

2013
Azacitidine pharmacokinetics in an adolescent patient with renal compromise.
    Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:5

    Topics: Acute Disease; Adolescent; Azacitidine; Chimerism; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Recurrence; Renal Insufficiency; Treatment Outcome

2007